| Autor: |
Tomomatsu T; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Shimizu H; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Yokokawa T; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Fukada I; Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research., Kawakami K; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Kobayashi K; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Aoyama T; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Suzuki W; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Sugisaki T; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Hashimoto K; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Asano M; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Mori Y; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research., Hara F; Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research., Takano T; Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research., Ohno S; Breast Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research., Yamaguchi M; Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research. |
| Abstrakt: |
This study aimed to estimate the medical costs associated with febrile neutropenia (FN) prophylaxis with pegfilgrastim and evaluate its impact on survival outcomes in daily practice in Japan. In this single-center retrospective study, we obtained data from 296 Japanese patients with breast cancer receiving fluorouracil, epirubicin, and cyclophosphamide (FEC)-100 chemotherapy; the patients were divided into the pegfilgrastim and non-pegfilgrastim groups. We analyzed the median costs of chemotherapy, drugs for all adverse events (AEs) and FN, and hospitalization due to FN. We also assessed the survival outcomes. The pegfilgrastim group showed a significantly higher median total cost (JPY 872320.0 vs. JPY 466715.0, p<0.001). This difference was associated with the prophylactic use of pegfilgrastim. The median costs of the drugs for all AE treatments were JPY 9030.4 and JPY 24690.6, with the non-pegfilgrastim group showing a significantly higher cost (p<0.001). In 11 patients hospitalized for FN management, no significant difference in hospitalization cost was observed between the pegfilgrastim and non-pegfilgrastim groups (JPY 512390.0 vs. JPY 307555.0, p=0.102). No significant difference in the 3-year overall survival was observed between the pegfilgrastim and non-pegfilgrastim groups (79.9% vs. 88.3%, p=0.672). In this study, although the total medical cost in daily practice increased because of primary prophylaxis with pegfilgrastim, the 3-year overall survival was not impacted by the use of pegfilgrastim. Our study data suggested that the primary prophylaxis pegfilgrastim should be used during FEC-100 chemotherapy based on the patient-related FN risk factors, instead of routine use. |
